Solid Biosciences Inc (SLDB): Price-to-Revenue Coefficient

Symbol and logo of brand Solid Bio (SLDB)

Historically, the development of Solid Biosciences Inc. (SLDB) has been driven by strict FDA oversight and the struggle to mitigate vector toxicity. The price-to-sales ratio reflects the current market valuation, where the 11.90 mark characterizes this parameter. Prospects are based on grants amid negative FCF, while business resilience relies on the non-cyclical demand for gene therapy, which remains independent of macroeconomic trends.

SLDB Solid Biosciences: P/S Multiple in the range 07/04/2022 - 08/19/2023

Metric breakdowns and analytics for Solid Bio (SLDB)

- current quotes and average value forecast:
Market Price solidbio.com|SLDB - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Solid Bio|SLDB - Enterprise Value
- company book value details:
Accounting Value per Share Solid Biosciences|SLDB - Book Capitalization|Market Capitalization to Book Value solidbio.com|SLDB - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Solid Biosciences Inc.|SLDB - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Solid Corp|SLDB - Company Aggregate Debts|Debt to Book Value Solid Bio|SLDB - Company Long-Term Debts|Short-Term Debt Solid Biosciences|Interim Coverage Ratio solidbio.com
- business earnings and investment ratios data:
SLDB - Net Income|Expected Net Income Solid Biosciences Inc.|SLDB - P/E Multiple|Market Cap to Projected Earnings Solid Biosciences Inc|SLDB - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Solid Bio|SLDB - Operating profit EBITDA|Net earnings per share for the last 12 months Solid Biosciences|SLDB - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months solidbio.com|SLDB - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Solid Biosciences Inc.
- issuer revenue and sales details:
SLDB - Company Revenue|Company Projected Revenue solidbio.com|SLDB - P/S Multiple|Market Cap to Projected Revenue Solid Bio
General company analysis:SLDB (solidbio.com)
Mass-produced product of solidbio.com

High FDA regulatory risks and pressure from approved gene therapy counterparts make the valuation of Solid Biosciences Inc. (SLDB) extremely sensitive to market expectations. By analyzing the revenue multiple dynamics, an investor can observe the price-to-sales ratio, which allows them to filter out speculative noise and determine the fair value of this high-risk biotech asset.

Competing companies

TEM - Price to Sales|Price-to-Revenue Ratio Qiagen QGEN|Price-to-Revenue Coefficient Ionis Pharmaceuticals, Inc. (IONS)|Repligen Corp. - P/S Multiple|Avidity Corp (RNA) - Market Cap to Revenue|CRSP: P/S Multiple|WGS - Price-to-Revenue Coefficient|RARE (Ultragenyx) - P/S Multiple|Price to Sales Beam Therapeutics Inc BEAM|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Market Cap to Revenue Ratio|P/S Multiple TXG (10x Genomics, Inc.)|NTLA - Market Cap to Revenue|Stoke Therapeutics, Inc. - P/S Multiple|Price to Sales BioLife Solutions Inc|Wave Life Sciences Corp (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|Market Cap to Revenue SION|PRME: Market Capitalization-to-Revenue Ratio|P/S Multiple TSHA|Price-to-Revenue Coefficient uniQure NV|Price-to-Revenue Ratio MeiraGTx PLC MGTX|RGNX: Market Cap to Revenue Ratio|Ocugen, Inc. - P/S Multiple|pacb.com (PACB) - Market Cap to Revenue|BNTC (Benitec Biopharma) - Market Cap to Revenue|DSGN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Rocket Pharmaceuticals Inc|4D Molecular Corp (FDMT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Lexeo Therapeutics (LXEO)|Price-to-Revenue Ratio KRRO (korrobio.com)|P/S Multiple EDIT (Editas Medicine)|SLN: Market Cap to Revenue Ratio|ProQR Therapeutics NV - P/S Multiple|CDXS: Price-to-Revenue Ratio|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio Metagenomi|Market Cap to Revenue Ratio DTIL (precisionbiosciences.com)|P/S Multiple GBIO|P/S Multiple Boundless Bio Inc (BOLD)|Price-to-Revenue Ratio Exicure XCUR|Price-to-Revenue Coefficient Imunon Inc (IMNN)|PHIO - Price-to-Revenue Ratio|Price to Sales Mustang Bio, Inc.|transcodetherapeutics.com (RNAZ) - Price-to-Revenue Ratio|BNGO (Bionano Genomics) - Price-to-Revenue Ratio|APDN (Applied DNA Sciences) - P/S Multiple|bluebirdbio.com (BLUE) - Price-to-Revenue Coefficient|P/S Multiple IPA|Omega Therapeutics Inc - Market Cap to Revenue Ratio|Singular Genomics Systems Inc - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals - P/S Multiple|TBIO: Price-to-Revenue Ratio|TCON: P/S Multiple|UBX - Price-to-Revenue Coefficient